Canine Atopic Dermatitis Market Share, Size, Trends, Industry Analysis Report, By Product (Glucocorticoids, Antihistamines, Immunosuppressants, Monoclonal Antibody, Others); By Mode of Administration; By Distribution Channel; By Region; Segment Forecast,

Canine Atopic Dermatitis Market Share, Size, Trends, Industry Analysis Report, By Product (Glucocorticoids, Antihistamines, Immunosuppressants, Monoclonal Antibody, Others); By Mode of Administration; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032

The global canine atopic dermatitis market size is expected to reach USD 2,841.59 million by 2032, according to a new study by Polaris Market Research. The report “Canine Atopic Dermatitis Market Share, Size, Trends, Industry Analysis Report, By Product (Glucocorticoids, Antihistamines, Immunosuppressants, Monoclonal Antibody, Others); By Mode of Administration; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Canine atopic dermatitis (CAD) is an inherited tendency to develop an itchy inflammatory skin condition associated with IgE antibodies, typically targeting environmental allergens. The disorder commonly affects dogs between six months and three years of age, manifesting as itching and secondary skin lesions in specific areas such as the face (mouth, eyes), concave aspect of the ventral abdomen, ear pinnae, interdigital skin, carpal and tarsal joints, flexor aspects of the elbow, and perineal area. Affected animals often exhibit behaviors like rubbing, licking, chewing, biting, or scratching, due to uneven hair loss, reddening, and thickening of the skin.

Market dynamics are significantly influenced by the increasing incidence of atopic dermatitis in dogs, linked to factors such as air pollution and allergens. This trend is expected to drive market growth in the forecast period. The growing demand for pet insurance, coupled with heightened concern among pet owners, is anticipated to boost the industry further. Additionally, increased research and development investments for launching products addressing canine atopic dermatitis, along with a robust product pipeline, are poised to contribute to industry growth. The expansion of insurance coverage is also expected to play a role in the industry's development.

However, certain challenges may impact market growth, including stringent regulations aimed at restricting the off-label use of human drugs for animals. The increase in the number of veterinary practitioners, hospitals, and clinics is anticipated to foster industry growth, but regulatory constraints on therapeutics may need to be revised. Overall, the market outlook is optimistic, with the potential for growth, given the concerted efforts to address canine atopic dermatitis and the evolving landscape of pet care and health.

As per a report from the American College of Veterinary Dermatology (ACVD) in 2017, approximately 10% to 15% of dogs were afflicted by canine atopic dermatitis. The exact etiology of this disease remains not entirely understood, although genetic abnormalities are identified as one of the primary factors. A study published in the American Journal of Veterinary Research revealed that golden retrievers in the U.K. faced a 50% risk of developing canine atopic dermatitis, attributed to geographic variations, a factor expected to contribute to revenue growth in the foreseeable future.

The increasing demand for pet insurance and growing concern among pet owners are poised to have a favorable impact on the market in the upcoming years. Additionally, stringent regulations enforced by the Food and Drug Administration (FDA) and other regulatory bodies to curb the off-label usage of human drugs in animals are catalyzing market growth.

Canine Atopic Dermatitis Market Report Highlights

The monoclonal antibodies segment accounted for the largest market share in 2023. These are designed to target specific pathways or proteins involved in the disease process. In the context of canine atopic dermatitis, these antibodies may be developed to address specific immune responses or inflammatory pathways associated with the condition.

In 2023, the retail segment held the highest market share due to various outlets, including specialized pet stores and veterinary clinics with retail sections. These outlets offer a diverse range of atopic dermatitis management products, which contribute to driving the market share.

In 2023, North America accounted for the largest market share due to the large population of pet owners in the region, contributing to a robust market for veterinary pharmaceuticals and products related to canine health.

The global key market players include AB Science SA, Bioceltix Spolka Akcyjna, Boehringer Ingelheim, Ceva Sante Animale, Dechra Pharmaceuticals Plc, Elanco, Elanco Animal Health Inc., Kindred Biosciences Inc., Merck and Co., Inc., Nextmune, Novartis AG, Toray Industries Inc., Vetoquinol UK Ltd., Vimian Group AB, Virbac, Zoetis Inc.

Polaris Market Research has segmented the canine atopic dermatitis market report based on product, mode of administration, distribution channel, and region:

Canine Atopic Dermatitis, Product Outlook (Revenue - USD Million, 2019 - 2032)

Glucocorticoids

Antihistamines

Immunosuppressants

Monoclonal Antibody

Others

Canine Atopic Dermatitis, Mode of Administration Outlook (Revenue - USD Million, 2019 - 2032)

Topical

Oral

Injectable

Canine Atopic Dermatitis, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)

Veterinary Hospitals/Clinics

Retail

E-commerce

Canine Atopic Dermatitis, Regional Outlook (Revenue - USD Million, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa